domingo, 27 de enero de 2019

Biosimilars and interchangeability: FDA's approach makes sense - STAT

Biosimilars and interchangeability: FDA's approach makes sense - STAT

First Opinion



STAT Plus: Biosimilars and interchangeability: The FDA’s science-based standards will ensure safety

By RICHARD MARKUS


ADOBE
The FDA's thorough and thoughtful approach to approving biosimilars will create an enduring biosimilars market with meaningful savings.

No hay comentarios: